Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
myelofibrosis
Biotech
Lilly’s $2.3B Ajax drug works ‘right out of the gate’
The early data showed the novel JAK2 inhibitor “started working right out of the gate, with a good safety profile,” Lilly’s Jake Van Naarden said.
Angus Liu
Jun 13, 2026 11:15am
Lilly pens $2.3B deal for next-gen JAK inhibitor biotech Ajax
Apr 27, 2026 8:25am
Fierce Pharma
Sanofi inks $1.5B deal for Sino Biopharm's novel asset
Mar 4, 2026 3:00am
Incyte scraps BET inhibitor and anti-CD122 drug
Oct 28, 2025 9:05am
Incyte scraps cancer-related anemia program after ph. 1/2 fail
Dec 13, 2024 2:30pm
Takeda pays Keros $200M upfront for rival to BMS' Reblozyl
Dec 3, 2024 7:30am
Fierce Pharma
Fierce Pharma
Fierce Pharma
Fierce Pharma
